|LETTER TO EDITOR
|Year : 2020 | Volume
| Issue : 2 | Page : 347-348
Philip et al.'s reply to Chandrasekharan et al. and Bagal et al.
Chepsy C Philip1, Anup J Devasia2
1 Regional Advanced Centre for Transplant, Hemato-Lymphoid Oncology and Marrow Diseases, Believers Church Medical College Hospital, Thiruvalla, Kerala, India
2 Department of Clinical Hematology, Christian Medical College, Vellore, Tamil Nadu, India
|Date of Submission||15-May-2020|
|Date of Decision||16-May-2020|
|Date of Acceptance||18-May-2020|
|Date of Web Publication||19-Jun-2020|
Chepsy C Philip
Regional Advanced Centre for Transplant, Hemato-Lymphoid Oncology and Marrow Diseases, Believers Church Medical College Hospital, Thiruvalla - 689 103, Kerala
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Philip CC, Devasia AJ. Philip et al.'s reply to Chandrasekharan et al. and Bagal et al. Cancer Res Stat Treat 2020;3:347-8
We thank Bagal et al. and Chandrasekharan et al. for their interest and comments on our recent article, “Treating hematolymphoid malignancies during COVID-19 in India: Challenges and potential approaches.”
We would like to reemphasize that the main intent of our review was to collate available evidence on this unique coronavirus disease 2019 (COVID-19) pandemic from the published literature and provide a framework for our colleagues on the strategies for the management of hematological malignancies, while awaiting more specific recommendations and guidelines from national societies. We understand that context is central to decision-making and have therefore discussed our limitations, highlighted medicine accessibility, and stressed on the need for medical professionals to decide on the appropriate diagnosis, advice, and line of care for each patient.
We appreciate and agree with the authors' comment that the retired doctors could likely be the most vulnerable during this pandemic. A degree of pragmatism is essential in our treatment decision-making. We also concur that testing for COVID-19 prior to treatment is rational. We recommend adhering to the national guidelines for testing, which are also strictly complied with at both our centers. In addition, in one center (CCP), the testing policy is in consultation with the district surveillance officer when the sample is sent to the state public laboratory. At the other center (AJD), testing is mandatory before each high-dose therapy and stem cell transplantation.
We are aware and acknowledge the efforts of our colleagues and centers that have adapted the protocols to best serve the interests of the patients. Information and data related to this pandemic are rapidly evolving, and we need to be prepared to adapt to this dynamic and evolving situation.
In conclusion, we concur that practices and guidance during this pandemic are in constant flux and that treatment of hematolymphoid malignancies in India during the COVID-19 pandemic is both complex and challenging.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Bagal B, Munot P, Nayak L. COVID-19 in hematological malignancies. Cancer Res Stat Treat 2020;3:345. [Full text]
Chandrasekharan A, Sreelesh KP, Gangadharan KV. Hematological malignancies in the time of COVID-19. Cancer Res Stat Treat 2020;3:343-4. [Full text]
Philip CC, Devasia AJ. Treating hematolymphoid malignancies during COVID-19 in India: Challenges and potential approaches. Cancer Res Stat Treat 2020;3 Suppl S1:59-64.